ViroPharma sells sales force to Aventis
This article was originally published in Pharmaceutical Approvals Monthly
Aventis plans to strengthen its presence in the respiratory disease market through the $15.4 mil. acquisition of ViroPharma's 200-rep sales force. ViroPharma reps already market Aventis' Nasacort AQ (triamcinolone acetonide) and the Allegra (fexofenadine) famil
You may also be interested in...
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.